Furthermore, serum levels of FST are increased in prostate cancer patients [19] and overexpression of FST occurs in tumours compared to normal prostate tissues [49], supporting a model where FST suppresses activin signalling‐mediated cell growth inhibition and promotes prostate cancer development and progression [50, 51]. Here, FST is linked to neoplasm.